168 related articles for article (PubMed ID: 3499251)
1. High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.
Diddens H; Teufel T; Niethammer D
Cancer Chemother Pharmacol; 1987; 20(2):128-32. PubMed ID: 3499251
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacologic rationale for high-dose methotrexate.
Jolivet J
NCI Monogr; 1987; (5):61-5. PubMed ID: 2448656
[TBL] [Abstract][Full Text] [Related]
3. Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.
Asai S; Miyachi H; Kobayashi H; Takemura Y; Ando Y
Cancer Sci; 2003 Feb; 94(2):210-4. PubMed ID: 12708499
[TBL] [Abstract][Full Text] [Related]
4. Biochemical control of high-dose methotrexate/Leucovorin rescue therapy.
Wilmanns W; Sauer H; Schalhorn A
Recent Results Cancer Res; 1980; 74():42-9. PubMed ID: 6969415
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells.
Boarman DM; Baram J; Allegra CJ
Biochem Pharmacol; 1990 Dec; 40(12):2651-60. PubMed ID: 2260989
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.
Browman GP; Goodyear MD; Levine MN; Russell R; Archibald SD; Young JE
J Clin Oncol; 1990 Feb; 8(2):203-8. PubMed ID: 2405105
[TBL] [Abstract][Full Text] [Related]
7. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
Skarin AT; Canellos GP
NCI Monogr; 1987; (5):71-6. PubMed ID: 3501548
[TBL] [Abstract][Full Text] [Related]
9. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.
Romanini A; Li WW; Colofiore JR; Bertino JR
J Natl Cancer Inst; 1992 Jul; 84(13):1033-8. PubMed ID: 1376779
[TBL] [Abstract][Full Text] [Related]
10. Amelioration by leucovorin of methotrexate developmental toxicity in rabbits.
DeSesso JM; Goeringer GC
Teratology; 1991 Mar; 43(3):201-15. PubMed ID: 2014483
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate: a critical reappraisal.
Ackland SP; Schilsky RL
J Clin Oncol; 1987 Dec; 5(12):2017-31. PubMed ID: 3316519
[TBL] [Abstract][Full Text] [Related]
12. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
15. The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.
Allen J; Rosen G; Juergens H; Mehta B
J Neurooncol; 1983; 1(1):39-44. PubMed ID: 6611387
[TBL] [Abstract][Full Text] [Related]
16. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children.
Camitta BM; Holcenberg JS
Med Pediatr Oncol; 1978; 5(1):55-9. PubMed ID: 370536
[TBL] [Abstract][Full Text] [Related]
17. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
18. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
19. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
20. DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines.
Neradil J; Pavlasova G; Sramek M; Kyr M; Veselska R; Sterba J
Oncol Rep; 2015 May; 33(5):2169-75. PubMed ID: 25739012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]